Full text is available at the source.
Abstract
Obesity, type 2 diabetes, and weight loss could increase the risk of fragility fractures.
- Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are commonly prescribed medications.
- The effects of GLP-1 RAs on bone health and fracture risk remain unclear.
- Increased fragility fracture risk is associated with obesity and type 2 diabetes.
- Weight loss may also contribute to higher fragility fracture risk.
Simplified